Effects of the DT-diaphorase inhibitor dicumarol on striatal monoamine levels in L-DOPA and L-deprenyl pre-treated rats

Neurotoxicity Research

Volumn 5, Issue 8, 2003, Pages 569-577

  Bustamante, Diego ^a   Bustamante, L ^a   Segura Aguilar, Juan ^a   Goiny, Michel ^b   Herrera Marschitz, Mario ^a,b  

^a UNIVERSITY OF CHILE   (Chile)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Basal Ganglia; Dicumarol; Dopamine; Parkinson's Disease; Rat; Selegiline

Indexed keywords

BIOGENIC AMINE; DICOUMAROL; ENZYME INHIBITOR; LEVODOPA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SELEGILINE;

ANIMAL; ARTICLE; COMPARATIVE STUDY; CORPUS STRIATUM; DRUG ANTAGONISM; DRUG EFFECT; MALE; METABOLISM; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; BIOGENIC MONOAMINES; CORPUS STRIATUM; DICUMAROL; ENZYME INHIBITORS; LEVODOPA; MALE; NAD(P)H DEHYDROGENASE (QUINONE); RATS; RATS, SPRAGUE-DAWLEY; SELEGILINE;

EID: 2442526420     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033177     Document Type: Article

References (43)

1. Asanuma M, I Mixazaki and N Ogawa (2003) Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson's Disease. Neurotoxicity Res. 5, 165-176.
2. Bach, AW, NC Lan, DL Johnson, CW Abel, ME Membenek, SW Kwan, PH Seeburg and JC Shih (1988) cDNA cloning of human liver monoamine oxidase A and B: Molecular basis of differences in enzymatic properties. Proc. Natl. Acad. Sci. USA 85, 4934-4938.
3. Baez S, Y Linderson and J Segura-Aguilar (1995) Superoxide dismutase and catalase enhance autoxidation during one-electron reduction of aminochrome by NADPH-Cytochrome P-450 reductase. Biochem. Molec. Med. 54, 12-18.
4. Butcher SP, IS Fairbrother, JS Kelly and GW Arbuthnott (1990) Effects of selective monoamine inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J. Neurochem. 55, 981-988.
5. Chen, Y, E Engidawork, F Loidl, E Dell'Anna, M Goiny, G Lubec, K Andersson and M Herrera-Marschitz (1997) Short-and long-term effects of perinatal asphyxia on monoamine, amino acid and glycolysis prduct levels measured in the basal ganglia of the rat. Dev. Brain Res. 104, 19-30.
6. Christensson-Nylander I, M Herrera-Marschitz, W Staines, T. Hökfelt, L Terenius, U Ungerstedt, C Cuello, WH Oertel and M Goldstein (1986) Striato-nigral dynorphin and substance P path-ways in the rat. I. Biochemical and immunohistochemical evidence. Exp. Brain Res. 64, 169-192.
7. Fahn S (1997) Levodopa-induced neurotoxicity. Does it represent a problem for the treatment of Parkinson's disease? CNS Drugs 8, 376-393.
8. Fahn S (1999) Parkinson's disease, the effect of l -DOPA, and the ELL-DOPA trial. Earlier vs. later l -DOPA. Arch. Neurol. 56, 256-261.
9. Gerlach M, MB Youdim and P Riederer (1996) Pharmacology of selegiline. Neurology 47(Suppl. 3), 137-145.
10. Graumann R, I Paris, P Martinez-Alvarado, P Rumanque, C Perez-Pastene, SP Cardena, P Marin, F Diaz-Grez, R Caviedes, P Caviedes and J Segura-Aguilar (2002) Oxidation of dopamine to aminochrome as a mechanism for neurodegeneration of dopaminergic systems in Parkinson's disease. Possible neuroprotective role of DT-diaphorase. Pol. J. Pharmacol. 54, 573-579.
11. Hallman H (1984) Neurochemical studies on central monoamine neurons: consequences of selective toxic lesions. Karolinska Institutet-Thesis, Stockholm, Sweden, pp 1-41.
12. Herrera-Marschitz M (1986) Neuropharmacology and functional anatomy of the basal ganglia. Karolinska Institutet-Thesis, Stockholm, Sweden, pp 1-79.
13. Herrera-Marschitz M and U Ungerstedt (1984) Evidence that striatal efferents relate to different dopamine receptors. Brain Res. 323, 269-278.
14. Herrera-Marschitz M, U Utsumi and U Ungerstedt (1990) Scoliosis in rats with experimentally-induced hemiparkinsonism: Dependence upon striatal dopamine denervation. J. Neurol. Neurosurg. Psych. 53, 39-43.
15. Herrera-Marschitz M, JJ Meana, WT O'Connor, M Goiny, MS Reid and U Ungerstedt (1992) Neuronal dependence of extracellular dopamine, acetylcholine, glutamate, aspartate and gamma-aminobutyric acid (GABA) measured simultaneously from rat neostriatum using in vivo microdialysis: Reciprocal interactions. Amino Acids 2, 157-179.
16. Herrera-Marschitz M, Z-B You, M Goiny, JJ Meana, R Silveira, O Godukhin, Y Chen, S Espinoza, E Pettersson, F Loidl, G Lubec, K Andersson, I Nylander, L Terenius and U Ungerstedt (1996) On the origin of extracellular glutamate levels monitored in the basal ganglia by in vivo microdialysis. J. Neurochem. 66, 1726-1735.
17. Hornykiewicz O (2000) L-DOPA: From biologically inactive amino acid to a successful therapeutic agent. Amino Acids 23, 65-70.
18. Kato T, B Dong, K Ishii and H Kinemuchi (1986) Brain dialysis: In vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats. J. Neurochem. 46, 1277-1282.
19. Knoll J (2000) Deprenyl (Selegiline): Past, present and future. Neurobiology 8, 179-199.
20. Knoll J and K Magyar (1972) Some puzzling effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol. 5, 393-408.
21. Kostrzewa RM, JP Kostrzewa and R Brus (2002) Neuroprotective and neurotoxic roles of levodopa (l -DOPA) in neurodegenerative disorders relating to Parkinson's disease. Amino Acids 23, 57-63.
22. Lamensdorf I, MB Youdim and JP Finberg (1996) Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J. Neurochem 67, 1532-1539.
23. Levitt P., JE Pintar and XO Breakefield (1982) Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotoninergic neurons. Proc. Natl. Acad. Sci. USA 79, 6385-6389.
24. Lind C, P Hoschstein and L Ernster (1982) DT-diaphorase as a quinone reductase: A cellular control device against semiquinone and superoxide radical formation. Arch. Biochem. Biophys. 216, 178-185.
25. Paxinos G and C Watson (1997) The Rat Brain in Stereotaxic Coordinates (Academic Press, New York).
26. Poewe WH and GK Wenning (1996) The natural history of Parkinson's disease. Neurology 47(Suppl. 3), 146-152.
27. Schultzberg M, J Segura-Aguilar and C Lind (1988) Distribution of DT diaphorase in the rat brain: Biochemical and immunohistochemical studies. Neuroscience 27, 763-776.
28. 3+ induced neurotoxicity of dopamine: Prevention of quinone derived oxygen toxicity by DT-diaphorase and superoxide dismutase. Chem. Biol. Interact. 72, 309-324.
29. Segura-Aguilar J, D Metodiewa and CJ Welch (1998) Metabolic activation of dopamine o -quinones to o -semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim. Biophys. Acta 1381, 1-6.
30. Segura-Aguilar J, D Metodiewa and S Baez (2001) The possible role of one-electron reduction of aminochrome in the neurodegenerative process of the dopaminergic system. Neurotoxicity Res. 3, 157-165.
31. 3+ to produce a 6-OH-dopamine like rotational behaviour. Neurotoxicity Res. 4, 127-131.
32. Strömberg I, M Herrera-Marschitz, L Hultgren, U Ungerstedt and L Olson (1984) Adrenal medullary implants in the dopamine-denervated rat striatum: I. Acute catecholamine levels in grafts and host caudate as determined by HPLC-electrochemistry and fluorescence histochemical image analysis. Brain Res. 297, 41-51.
33. Sulzer D and S Rayport (1990) Amphetamine and the psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: A mechanism of action. Neuron 5, 797-808.
34. Sulzer D, TK Chen, YY Lau, H Kristensen, S Rayport and A Ewig (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15, 4102-4108.
35. Sulzer D and L Zecca (2000) Intraneuronal dopamine-quinone synthesis: A review. Neurotoxicity Res. 1, 181-195.
36. Sulzer D, J Bogulavsky, KE Larsen, G Behr, E Karatekin, MH Kleinman, N Turro, D Krantz, RH Edwards, LA Greene and L Zecca (2000) Neuromelanin biosynthesis is driven by excess cuytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. USA 97, 11869-11874.
37. Torrres GE, RR Gainetdinov and MG Caron (2003) Plasma membrane monoamine transporters: Structure, regulation and function. Nature Rev. Neurosci. 4, 13-25.
38. Ungerstedt U (1971) Stereotaxic mapping of the monoamine pathway in the rat brain. Acta Physiol. Scand. 367(Suppl), 1-48.
39. Ungerstedt U and M Herrera-Marschitz (1981) Behavioural pharmacology of dopamine receptor mechanisms. In: L. Stjärne, P Hedqvist, H Lagerkrantz and A Wenmalm (Eds.), Chemical Neurotransmission: 75 years (Academic Press, New York), pp. 481-494.
40. Ungerstedt U, M Herrera-Marschitz, U Jungnelius, L Stähle, U Tossman and T. Zetterström (1982) Dopamine synaptic mechanisms reflected in studies combining behavioural recordings and brain dialysis. Adv. Biosci. 37, 219-231.
41. Westerink BHC (1985) Commentary: Sequence and significance of dopamine metabolism in the rat brain. Neurochem. Int. 7, 221-227.
42. Yahr MD, RC Duvoisin, MJ Schear, RE Barrett and MM Hoen (1969) Treatment of parkinsonism with levodopa. Arch. Neurol. 21, 343-354.
43. Zetterström T, M Herrera-Marschitz and U Ungerstedt (1986) Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxydopamine denervated rats using intracerebral dialysis. Brain Res. 376, 1-7.